In the absence of evidence that the cholesterol fighter Vytorin works better than a cheaper drug known as a statin, patients should turn back to using statins and other proven drugs, an expert panel said on Sunday.

Ahead of the weekend, CNBC asks the experts where investors should place their bets.

The pharmaceutical sector faces the looming "patent cliff" -- but Credit Suisse's Catherine Arnold finds lots of opportunities in the sector for the careful investor.

Stocks closed mixed  Tuesday after an earlier rally inspired by Warren Buffett swooping into the situation with bond insurers and banks teaming up to stop foreclosures.

Most of the 30 stocks in the Dow were higher Tuesday after billionaire investor Warren Buffett offered a reinsurance plan to troubled bond insurers and top mortgage lenders unveiled a plan aimed at freezing foreclosures.

Schering-Plough Tuesday reported a quarterly loss as special charges from its acquisition of Organon Biosciences late last year offset sharply higher sales, but results beat Wall Street expectations.

Most of the 30 stocks in the Dow were higher Tuesday after billionaire investor Warren Buffett offered a reinsurance plan to troubled bond insurers and top mortgage lenders unveiled a plan aimed at freezing foreclosures.

U.S. regulators said  they would review whether to take action over the popular cholesterol drug Vytorin after a study showed it was no better than a generic in preventing the build-up of fatty plaque.